PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15919106-1 2005 OBJECTIVE: Lysophosphatidic acid (LPA) stimulates ovarian tumor growth partially via induction of VEGF expression through transcriptional activation. lysophosphatidic acid 11-32 vascular endothelial growth factor A Homo sapiens 98-102 15919106-1 2005 OBJECTIVE: Lysophosphatidic acid (LPA) stimulates ovarian tumor growth partially via induction of VEGF expression through transcriptional activation. lysophosphatidic acid 34-37 vascular endothelial growth factor A Homo sapiens 98-102 15919106-9 2005 RESULTS: Using a VEGF neutralizing monoclonal antibody (mAb), we show that LPA-induced EOC invasion is dependent upon VEGF. lysophosphatidic acid 75-78 vascular endothelial growth factor A Homo sapiens 17-21 15919106-9 2005 RESULTS: Using a VEGF neutralizing monoclonal antibody (mAb), we show that LPA-induced EOC invasion is dependent upon VEGF. lysophosphatidic acid 75-78 vascular endothelial growth factor A Homo sapiens 118-122 15919106-14 2005 CONCLUSIONS: Our results show that LPA-induced EOC invasion is at least partially mediated by VEGF. lysophosphatidic acid 35-38 vascular endothelial growth factor A Homo sapiens 94-98 12668280-5 2003 These results suggested that LPA(2) and LPA(3) may be involved in VEGF expression mediated by LPA signals in human ovarian oncogenesis. lysophosphatidic acid 29-32 vascular endothelial growth factor A Homo sapiens 66-70 12759391-1 2003 BACKGROUND: Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. lysophosphatidic acid 12-33 vascular endothelial growth factor A Homo sapiens 178-212 12759391-1 2003 BACKGROUND: Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. lysophosphatidic acid 12-33 vascular endothelial growth factor A Homo sapiens 214-218 12759391-1 2003 BACKGROUND: Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. lysophosphatidic acid 35-38 vascular endothelial growth factor A Homo sapiens 178-212 12759391-1 2003 BACKGROUND: Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. lysophosphatidic acid 35-38 vascular endothelial growth factor A Homo sapiens 214-218 24131310-8 2014 The addition of 25 muM LPA enhanced vascular endothelial growth factor (VEGF) secretion by MSC in all conditions, but VEGF availability was not responsible for protection against apoptosis. lysophosphatidic acid 23-26 vascular endothelial growth factor A Homo sapiens 36-70 10645770-5 1999 The chemotactic response induced by PA and LPA was similar in intensity to that observed with optimal levels of the known protein endothelial cell chemoattractants, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). lysophosphatidic acid 43-46 vascular endothelial growth factor A Homo sapiens 207-241 10645770-5 1999 The chemotactic response induced by PA and LPA was similar in intensity to that observed with optimal levels of the known protein endothelial cell chemoattractants, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). lysophosphatidic acid 43-46 vascular endothelial growth factor A Homo sapiens 243-247 33916643-6 2021 Moreover, LPA treatment augmented VEGF transcription, a known PR target. lysophosphatidic acid 10-13 vascular endothelial growth factor A Homo sapiens 34-38 24879414-11 2014 Angiogenin, IGFBP-1, IL-8, MCP-1, MMP-9, and VEGF mRNA and protein expressions were significantly enhanced in LPA-treated chondrocytes. lysophosphatidic acid 110-113 vascular endothelial growth factor A Homo sapiens 45-49 24879414-13 2014 Pretreatment with the Gi/o type G protein inhibitor, pertussis toxin (PTX), and the NF-kB inhibitor, PDTC, significantly inhibited LPA-induced angiogenin, IGFBP-1, IL-8, MCP-1, MMP-9, and VEGF expressions in chondrocytes. lysophosphatidic acid 131-134 vascular endothelial growth factor A Homo sapiens 188-192 11353786-0 2001 Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. lysophosphatidic acid 0-21 vascular endothelial growth factor A Homo sapiens 35-69 11353786-4 2001 METHODS: VEGF expression was examined in a simian virus 40 T-antigen-immortalized ovarian surface epithelial cell line (IOSE-29) and in ovarian cancer cell lines (OVCAR-3, SKOV-3, and CAOV-3) treated with LPA. lysophosphatidic acid 205-208 vascular endothelial growth factor A Homo sapiens 9-13 11353786-8 2001 RESULTS: LPA treatment increased steady-state VEGF messenger RNA (mRNA) levels in OVCAR-3 cells in a time- and dose-dependent fashion and stimulated VEGF promoter activity without prolonging mRNA half-life in these cells, but LPA had little effect on IOSE-29 cells. lysophosphatidic acid 9-12 vascular endothelial growth factor A Homo sapiens 46-50 11353786-8 2001 RESULTS: LPA treatment increased steady-state VEGF messenger RNA (mRNA) levels in OVCAR-3 cells in a time- and dose-dependent fashion and stimulated VEGF promoter activity without prolonging mRNA half-life in these cells, but LPA had little effect on IOSE-29 cells. lysophosphatidic acid 9-12 vascular endothelial growth factor A Homo sapiens 149-153 24131310-8 2014 The addition of 25 muM LPA enhanced vascular endothelial growth factor (VEGF) secretion by MSC in all conditions, but VEGF availability was not responsible for protection against apoptosis. lysophosphatidic acid 23-26 vascular endothelial growth factor A Homo sapiens 72-76 24113377-3 2013 We have previously demonstrated that LPA enhances vascular endothelial growth factor (VEGF)-C expression in PC-3 cells by activating the generation of reactive oxygen species (ROS), which is known to be an important mediator in cancer progression. lysophosphatidic acid 37-40 vascular endothelial growth factor A Homo sapiens 50-84 24113377-3 2013 We have previously demonstrated that LPA enhances vascular endothelial growth factor (VEGF)-C expression in PC-3 cells by activating the generation of reactive oxygen species (ROS), which is known to be an important mediator in cancer progression. lysophosphatidic acid 37-40 vascular endothelial growth factor A Homo sapiens 86-90 21782227-0 2011 The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). lysophosphatidic acid 31-52 vascular endothelial growth factor A Homo sapiens 67-71 23831623-0 2013 Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells. lysophosphatidic acid 39-60 vascular endothelial growth factor A Homo sapiens 69-105 23831623-1 2013 Lysophosphatidic acid (LPA) is a lipid growth factor with multiple biological functions and has been shown to stimulate cancer cell secretion of vascular endothelial growth factor-A (VEGF-A) and trigger angiogenesis. lysophosphatidic acid 0-21 vascular endothelial growth factor A Homo sapiens 145-181 23831623-1 2013 Lysophosphatidic acid (LPA) is a lipid growth factor with multiple biological functions and has been shown to stimulate cancer cell secretion of vascular endothelial growth factor-A (VEGF-A) and trigger angiogenesis. lysophosphatidic acid 0-21 vascular endothelial growth factor A Homo sapiens 183-189 23831623-1 2013 Lysophosphatidic acid (LPA) is a lipid growth factor with multiple biological functions and has been shown to stimulate cancer cell secretion of vascular endothelial growth factor-A (VEGF-A) and trigger angiogenesis. lysophosphatidic acid 23-26 vascular endothelial growth factor A Homo sapiens 145-181 23831623-1 2013 Lysophosphatidic acid (LPA) is a lipid growth factor with multiple biological functions and has been shown to stimulate cancer cell secretion of vascular endothelial growth factor-A (VEGF-A) and trigger angiogenesis. lysophosphatidic acid 23-26 vascular endothelial growth factor A Homo sapiens 183-189 23831623-3 2013 In this study, we first confirmed the ability of LPA to induce VEGF-A expression in PC-3 cells and then validated that LPA-induced VEGF-A expression was regulated by HIF-1alpha and ARNT through phosphatidylinositol 3-kinase activation. lysophosphatidic acid 49-52 vascular endothelial growth factor A Homo sapiens 63-69 23831623-3 2013 In this study, we first confirmed the ability of LPA to induce VEGF-A expression in PC-3 cells and then validated that LPA-induced VEGF-A expression was regulated by HIF-1alpha and ARNT through phosphatidylinositol 3-kinase activation. lysophosphatidic acid 119-122 vascular endothelial growth factor A Homo sapiens 63-69 23831623-3 2013 In this study, we first confirmed the ability of LPA to induce VEGF-A expression in PC-3 cells and then validated that LPA-induced VEGF-A expression was regulated by HIF-1alpha and ARNT through phosphatidylinositol 3-kinase activation. lysophosphatidic acid 119-122 vascular endothelial growth factor A Homo sapiens 131-137 23831623-5 2013 Since ARNT is a common dimerization partner of AHR and HIF-1alpha, we hypothesized that AHR might suppress LPA-induced VEGF-A expression in PC-3 cells by competing with HIF-1alpha for ARNT. lysophosphatidic acid 107-110 vascular endothelial growth factor A Homo sapiens 119-125 23831623-6 2013 Here we demonstrated that overexpression and ligand activation of AHR inhibited HIF-1-mediated VEGF-A induction by LPA treatment of PC-3 cells. lysophosphatidic acid 115-118 vascular endothelial growth factor A Homo sapiens 95-101 22911748-0 2012 Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. lysophosphatidic acid 0-21 vascular endothelial growth factor A Homo sapiens 31-65 21782227-0 2011 The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). lysophosphatidic acid 54-57 vascular endothelial growth factor A Homo sapiens 67-71 21782227-1 2011 OBJECTIVES: Our previous report has implicated the involvement of VEGF-VEGFR-2 h signaling in LPA-induced EOC invasion. lysophosphatidic acid 94-97 vascular endothelial growth factor A Homo sapiens 66-70 21782227-3 2011 In the present study, we systematically examined the signal transduction pathways activated by LPA and further evaluated whether LPA"s effect on VEGF-VEGFR-2 signaling and EOC invasion was mediated by the activation of NF-kappaB pathway. lysophosphatidic acid 129-132 vascular endothelial growth factor A Homo sapiens 145-149 21782227-8 2011 In addition, treatment with an NF-kappaB pathway activation inhibitor, at 10 muM, significantly decreased LPA-induced VEGF(121), VEGF(165) and VEGFR-2 mRNA expression and VEGF secretion, as well as LPA-induced SKOV3 invasion (p<0.05). lysophosphatidic acid 106-109 vascular endothelial growth factor A Homo sapiens 118-122 21782227-8 2011 In addition, treatment with an NF-kappaB pathway activation inhibitor, at 10 muM, significantly decreased LPA-induced VEGF(121), VEGF(165) and VEGFR-2 mRNA expression and VEGF secretion, as well as LPA-induced SKOV3 invasion (p<0.05). lysophosphatidic acid 106-109 vascular endothelial growth factor A Homo sapiens 129-133 21782227-8 2011 In addition, treatment with an NF-kappaB pathway activation inhibitor, at 10 muM, significantly decreased LPA-induced VEGF(121), VEGF(165) and VEGFR-2 mRNA expression and VEGF secretion, as well as LPA-induced SKOV3 invasion (p<0.05). lysophosphatidic acid 106-109 vascular endothelial growth factor A Homo sapiens 129-133 21782227-9 2011 When combined with an EGFR inhibitor, NF-kappaB pathway inhibition exhibited a significantly stronger effect than used alone (p<0.05) on reducing LPA-induced VEGF secretion and cell invasion. lysophosphatidic acid 149-152 vascular endothelial growth factor A Homo sapiens 161-165 21782227-11 2011 CONCLUSIONS: These results suggest that the NF-kappaB pathway plays an important role in LPA-induced VEGF signaling and EOC invasion and targeting this pathway may reveal potential therapeutic options for metastatic EOC. lysophosphatidic acid 89-92 vascular endothelial growth factor A Homo sapiens 101-105 20197381-3 2010 VEGF stimulated expression of ATX and LPA1, a receptor for the ATX enzymatic product lysophosphatidic acid (LPA), in human umbilical vein endothelial cells. lysophosphatidic acid 85-106 vascular endothelial growth factor A Homo sapiens 0-4 20177148-0 2010 Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. lysophosphatidic acid 23-44 vascular endothelial growth factor A Homo sapiens 69-73 20177148-8 2010 LPA activated RhoA in hASCs and pretreatment with the Rho kinase inhibitor Y27632 completely abrogated the LPA-induced expression of alpha-SMA, SDF-1, and VEGF in hASCs. lysophosphatidic acid 0-3 vascular endothelial growth factor A Homo sapiens 155-159 20177148-10 2010 LPA-induced VEGF secretion was inhibited by LY294002, whereas LPA-induced SDF-1 secretion was markedly attenuated by U0126, U73122, and LY294002. lysophosphatidic acid 0-3 vascular endothelial growth factor A Homo sapiens 12-16 20197381-3 2010 VEGF stimulated expression of ATX and LPA1, a receptor for the ATX enzymatic product lysophosphatidic acid (LPA), in human umbilical vein endothelial cells. lysophosphatidic acid 38-41 vascular endothelial growth factor A Homo sapiens 0-4 19765808-2 2009 We have previously reported the regulation of epithelial ovarian cancer (EOC) invasion and migration by VEGF and the implication of VEGF-VEGFR-2 axis in lysophosphatidic acid (LPA)-induced EOC invasion. lysophosphatidic acid 153-174 vascular endothelial growth factor A Homo sapiens 132-136 19765808-2 2009 We have previously reported the regulation of epithelial ovarian cancer (EOC) invasion and migration by VEGF and the implication of VEGF-VEGFR-2 axis in lysophosphatidic acid (LPA)-induced EOC invasion. lysophosphatidic acid 176-179 vascular endothelial growth factor A Homo sapiens 132-136 19765808-8 2009 In addition, LPA, at 20 muM, significantly induced the expression of VEGF(121), VEGF(165), and VEGFR-2 in SKOV3 and DOV13 cells (P<0.05). lysophosphatidic acid 13-16 vascular endothelial growth factor A Homo sapiens 69-73 19765808-8 2009 In addition, LPA, at 20 muM, significantly induced the expression of VEGF(121), VEGF(165), and VEGFR-2 in SKOV3 and DOV13 cells (P<0.05). lysophosphatidic acid 13-16 vascular endothelial growth factor A Homo sapiens 80-84 19860625-6 2009 In contrast, plasma levels of VEGF are elevated in patients with CLL compared to healthy controls and LPA treatment induced VEGF secretion in CLL cells. lysophosphatidic acid 102-105 vascular endothelial growth factor A Homo sapiens 30-34 19860625-6 2009 In contrast, plasma levels of VEGF are elevated in patients with CLL compared to healthy controls and LPA treatment induced VEGF secretion in CLL cells. lysophosphatidic acid 102-105 vascular endothelial growth factor A Homo sapiens 124-128 18642114-2 2008 Previous studies have shown that LPA enhances vascular endothelial growth factor-A (VEGF-A) expression in cancer cells and promotes angiogenesis process. lysophosphatidic acid 33-36 vascular endothelial growth factor A Homo sapiens 46-82 19147754-0 2009 Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. lysophosphatidic acid 23-44 vascular endothelial growth factor A Homo sapiens 67-101 19147754-1 2009 PURPOSE: Lysophosphatidic acid (LPA), which is present in ascites of ovarian cancer patients, stimulates expression of vascular endothelial growth factor (VEGF). lysophosphatidic acid 9-30 vascular endothelial growth factor A Homo sapiens 119-153 19147754-1 2009 PURPOSE: Lysophosphatidic acid (LPA), which is present in ascites of ovarian cancer patients, stimulates expression of vascular endothelial growth factor (VEGF). lysophosphatidic acid 9-30 vascular endothelial growth factor A Homo sapiens 155-159 19147754-1 2009 PURPOSE: Lysophosphatidic acid (LPA), which is present in ascites of ovarian cancer patients, stimulates expression of vascular endothelial growth factor (VEGF). lysophosphatidic acid 32-35 vascular endothelial growth factor A Homo sapiens 119-153 19147754-1 2009 PURPOSE: Lysophosphatidic acid (LPA), which is present in ascites of ovarian cancer patients, stimulates expression of vascular endothelial growth factor (VEGF). lysophosphatidic acid 32-35 vascular endothelial growth factor A Homo sapiens 155-159 19147754-8 2009 Blockade of Rho, ROCK, or c-Myc reduced LPA-dependent VEGF production and promoter activation, suggesting that the G12/13-Rho-ROCK-c-Myc cascade partially contributes to VEGF induction by LPA. lysophosphatidic acid 40-43 vascular endothelial growth factor A Homo sapiens 54-58 19147754-8 2009 Blockade of Rho, ROCK, or c-Myc reduced LPA-dependent VEGF production and promoter activation, suggesting that the G12/13-Rho-ROCK-c-Myc cascade partially contributes to VEGF induction by LPA. lysophosphatidic acid 40-43 vascular endothelial growth factor A Homo sapiens 170-174 19147754-11 2009 The silencing of Sp-1 expression with small interfering RNA or inhibition of Sp-1 with pharmacologic inhibitors blocked VEGF production induced by LPA. lysophosphatidic acid 147-150 vascular endothelial growth factor A Homo sapiens 120-124 19147754-12 2009 CONCLUSIONS: LPA stimulates hypoxia-inducible factor-1-independent VEGF expression to promote tumor angiogenesis through activation of the c-Myc and Sp-1 transcription factors. lysophosphatidic acid 13-16 vascular endothelial growth factor A Homo sapiens 67-71 18617617-7 2008 The effects of LPA on the expression of vascular endothelial growth factor, IL-6, and IL-8 were examined. lysophosphatidic acid 15-18 vascular endothelial growth factor A Homo sapiens 40-74 19193014-5 2009 Moreover, transplantation of LPA-treated MSCs enhanced capillary density determined by immunostaining for platelet endothelial cell adhesion molecule (PECAM)-1, and it is also found that LPA enhanced vascular endothelial growth factor (VEGF) release from MSCs under hypoxia/SD in vitro. lysophosphatidic acid 29-32 vascular endothelial growth factor A Homo sapiens 200-234 19193014-5 2009 Moreover, transplantation of LPA-treated MSCs enhanced capillary density determined by immunostaining for platelet endothelial cell adhesion molecule (PECAM)-1, and it is also found that LPA enhanced vascular endothelial growth factor (VEGF) release from MSCs under hypoxia/SD in vitro. lysophosphatidic acid 29-32 vascular endothelial growth factor A Homo sapiens 236-240 19193014-5 2009 Moreover, transplantation of LPA-treated MSCs enhanced capillary density determined by immunostaining for platelet endothelial cell adhesion molecule (PECAM)-1, and it is also found that LPA enhanced vascular endothelial growth factor (VEGF) release from MSCs under hypoxia/SD in vitro. lysophosphatidic acid 187-190 vascular endothelial growth factor A Homo sapiens 200-234 19193014-5 2009 Moreover, transplantation of LPA-treated MSCs enhanced capillary density determined by immunostaining for platelet endothelial cell adhesion molecule (PECAM)-1, and it is also found that LPA enhanced vascular endothelial growth factor (VEGF) release from MSCs under hypoxia/SD in vitro. lysophosphatidic acid 187-190 vascular endothelial growth factor A Homo sapiens 236-240 18642114-2 2008 Previous studies have shown that LPA enhances vascular endothelial growth factor-A (VEGF-A) expression in cancer cells and promotes angiogenesis process. lysophosphatidic acid 33-36 vascular endothelial growth factor A Homo sapiens 84-90 18337445-5 2008 Exogenous addition of VEGF-A to cultured cells induces ATX expression and secretion, resulting in increased extracellular LPA production. lysophosphatidic acid 122-125 vascular endothelial growth factor A Homo sapiens 22-28 18396013-10 2008 Taken together, this indicates that LPA contributes to VEGF production in B cell malignancies leading to cell survival. lysophosphatidic acid 36-39 vascular endothelial growth factor A Homo sapiens 55-59 18396013-0 2008 Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. lysophosphatidic acid 0-21 vascular endothelial growth factor A Homo sapiens 54-58 18396013-0 2008 Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. lysophosphatidic acid 23-26 vascular endothelial growth factor A Homo sapiens 54-58 18396013-3 2008 Herein, we demonstrate that lysophosphatidic acid (LPA) induces mRNA expression of VEGF in the multiple myeloma cell line, U266, the Burkitt"s lymphoma cell line, BJAB, and the chronic lymphocytic leukemia (CLL)-like cell line, I-83. lysophosphatidic acid 28-49 vascular endothelial growth factor A Homo sapiens 83-87 18396013-3 2008 Herein, we demonstrate that lysophosphatidic acid (LPA) induces mRNA expression of VEGF in the multiple myeloma cell line, U266, the Burkitt"s lymphoma cell line, BJAB, and the chronic lymphocytic leukemia (CLL)-like cell line, I-83. lysophosphatidic acid 51-54 vascular endothelial growth factor A Homo sapiens 83-87 18396013-5 2008 Secretion of VEGF was also increased in these cells following LPA treatment. lysophosphatidic acid 62-65 vascular endothelial growth factor A Homo sapiens 13-17 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 35-38 vascular endothelial growth factor A Homo sapiens 16-20 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 35-38 vascular endothelial growth factor A Homo sapiens 200-204 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 188-191 vascular endothelial growth factor A Homo sapiens 16-20 18396013-7 2008 The increase in VEGF expression by LPA is mediated by the activation of c-Jun N-terminal Kinase (JNK) and transcription factor NFkappaB since blocking JNK or NFkappaB activation inhibited LPA induced VEGF expression. lysophosphatidic acid 188-191 vascular endothelial growth factor A Homo sapiens 200-204 18396013-8 2008 Furthermore, we have demonstrated that LPA protects cells from apoptosis and blocking activation of both VEGFR1 and VEGFR2 using a VEGF receptor kinase inhibitor prevented LPA survival responses. lysophosphatidic acid 39-42 vascular endothelial growth factor A Homo sapiens 105-109 18396013-8 2008 Furthermore, we have demonstrated that LPA protects cells from apoptosis and blocking activation of both VEGFR1 and VEGFR2 using a VEGF receptor kinase inhibitor prevented LPA survival responses. lysophosphatidic acid 172-175 vascular endothelial growth factor A Homo sapiens 105-109 18171700-8 2008 The effects of LPA on the expression of IL-6, IL-8, and vascular endothelial growth factor were examined. lysophosphatidic acid 15-18 vascular endothelial growth factor A Homo sapiens 56-90 18337445-6 2008 This elevated LPA, acting through LPA(4), modulates VEGF responsiveness by inducing VEGF receptor (VEGFR)-2 expression. lysophosphatidic acid 14-17 vascular endothelial growth factor A Homo sapiens 52-56 17919812-0 2007 Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. lysophosphatidic acid 17-20 vascular endothelial growth factor A Homo sapiens 44-48 17919812-3 2007 Our results show that LPA treatment under hypoxia increases HIF-1alpha protein level, which leads to increased expression of VEGF protein and mRNA. lysophosphatidic acid 22-25 vascular endothelial growth factor A Homo sapiens 125-129 17919812-6 2007 Collectively, these results show that LPA under hypoxic condition enhances cell migration through the sequential induction of HIF-1alpha and VEGF, and that this enhancement is efficiently blocked by resveratrol. lysophosphatidic acid 38-41 vascular endothelial growth factor A Homo sapiens 141-145 17085645-0 2006 Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. lysophosphatidic acid 63-84 vascular endothelial growth factor A Homo sapiens 93-127 17085645-3 2006 In the present study, we investigated whether LPA activates hypoxia inducible factor-1 (HIF-1), a key transcriptional complex in tumor progression and metastasis, thereby increasing the expression of VEGF. lysophosphatidic acid 46-49 vascular endothelial growth factor A Homo sapiens 200-204 17085645-5 2006 Specific HIF-1alpha small interfering RNA was transfected to various cancer cells to determine the role of HIF-1alpha in LPA-induced VEGF expression. lysophosphatidic acid 121-124 vascular endothelial growth factor A Homo sapiens 133-137 17085645-6 2006 RESULTS: LPA induced expressions of VEGF and HIF-1alpha in OVCAR-3, CAOV-3, PC-3, and SK-Hep1 cells but not in SKOV-3 and Hep-3B cells. lysophosphatidic acid 9-12 vascular endothelial growth factor A Homo sapiens 36-40 17085645-7 2006 In OVCAR-3 and PC-3 cells, the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin/p70S6K and p42/p44 mitogen-activated protein kinase pathways were required for LPA-induced HIF-1alpha and VEGF expressions, whereas only the phosphoinositide 3-kinase/mammalian target of rapamycin/p70S6K pathway was important in SK-Hep1 cells. lysophosphatidic acid 170-173 vascular endothelial growth factor A Homo sapiens 197-201 17085645-8 2006 Immunofluorescence microscopy assay showed translocation of HIF-1alpha to nucleus by LPA, and chromatin immunoprecipitation assay revealed the binding of HIF-1alpha to the promoter of VEGF by LPA. lysophosphatidic acid 192-195 vascular endothelial growth factor A Homo sapiens 184-188 17085645-10 2006 CONCLUSIONS: Our results show for the first time that LPA induces VEGF via HIF-1alpha activation and reveal a critical role of HIF-1alpha in LPA-induced cancer cell proliferation and angiogenesis. lysophosphatidic acid 54-57 vascular endothelial growth factor A Homo sapiens 66-70